US appeals court ruling gives Teva boost over Cozaar/Hyzaar exclusivity
This article was originally published in Scrip
Executive Summary
A federal appeals court has ruled in favour of Teva Pharmaceutical Industries and overturned a lower court decision which held that the firm had forfeited 180 days of marketing exclusivity for its generic versions of Merck and Co's antihypertensives Cozaar (losartan potassium) and Hyzaar (losartan plus hydrochlorothiazide).